AKTS (Aktis Oncology) Cash per Share: $9.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTS Aktis Oncology Inc AKTS
12 GF Score
Price $27.05
! 1 Warning Sign
View Full Analysis

What is Aktis Oncology Cash per Share?

Aktis Oncology AKTS +1.27% 12 Cash per Share is $9.35 as of Jun. 2026. GuruFocus rates AKTS with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Aktis Oncology's Cash per Share for the quarter that ended in Jun. 2026 was $9.35.

Aktis Oncology  (NAS:AKTS) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Aktis Oncology Cash per Share Related Terms

Aktis Oncology Cash per Share Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Cash per Share Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Cash per Share
2.45 1.86 5.66 4.32

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.69 4.32 9.74 9.35
AKTS
12GF Score
Aktis Oncology Inc AKTS
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Aktis Oncology's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=226.787/52.52
=4.32

Aktis Oncology's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=517.32/55.32
=9.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $9.35 mean?
Aktis Oncology (AKTS) has a Cash per Share of $9.35 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Aktis Oncology and its competitors.
Is Aktis Oncology's Cash per Share too high?
Aktis Oncology's current Cash per Share is $9.35. Overall, Aktis Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Cash per Share compare to IMTX and REPL?
Aktis Oncology's Cash per Share of $9.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Aktis Oncology and its competitors. Aktis Oncology's current Cash per Share is $9.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Cash per Share of $9.35. The current Cash per Share is $9.35. Aktis Oncology's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Cash per Share is $9.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
12GF Score

Get the complete analysis for AKTS

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.05
Price